| 1. |
- Raykova, Doroteya, 1986-, et al.
(författare)
-
A method for Boolean analysis of protein interactions at a molecular level
- 2022
-
Ingår i: Nature Communications. - : Springer Nature. - 2041-1723. ; 13:1
-
Tidskriftsartikel (refereegranskat)abstract
- Determination of interactions between native proteins in cells is important for understanding function. Here the authors report MolBoolean as a method to detect interactions between endogenous proteins in subcellular compartments, using antibody-DNA conjugates for identification and signal amplification. Determining the levels of protein-protein interactions is essential for the analysis of signaling within the cell, characterization of mutation effects, protein function and activation in health and disease, among others. Herein, we describe MolBoolean - a method to detect interactions between endogenous proteins in various subcellular compartments, utilizing antibody-DNA conjugates for identification and signal amplification. In contrast to proximity ligation assays, MolBoolean simultaneously indicates the relative abundances of protein A and B not interacting with each other, as well as the pool of A and B proteins that are proximal enough to be considered an AB complex. MolBoolean is applicable both in fixed cells and tissue sections. The specific and quantifiable data that the method generates provide opportunities for both diagnostic use and medical research.
|
|
| 2. |
- Bergström, Göran, 1964, et al.
(författare)
-
Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population
- 2021
-
Ingår i: Circulation. - Philadelphia : American Heart Association. - 0009-7322 .- 1524-4539. ; 144:12, s. 916-929
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Early detection of coronary atherosclerosis using coronary computed tomography angiography (CCTA), in addition to coronary artery calcification (CAC) scoring, may help inform prevention strategies. We used CCTA to determine the prevalence, severity, and characteristics of coronary atherosclerosis and its association with CAC scores in a general population.Methods: We recruited 30 154 randomly invited individuals age 50 to 64 years to SCAPIS (the Swedish Cardiopulmonary Bioimage Study). The study includes individuals without known coronary heart disease (ie, no previous myocardial infarctions or cardiac procedures) and with high-quality results from CCTA and CAC imaging performed using dedicated dual-source CT scanners. Noncontrast images were scored for CAC. CCTA images were visually read and scored for coronary atherosclerosis per segment (defined as no atherosclerosis, 1% to 49% stenosis, or ≥50% stenosis). External validity of prevalence estimates was evaluated using inverse probability for participation weighting and Swedish register data.Results: In total, 25 182 individuals without known coronary heart disease were included (50.6% women). Any CCTA-detected atherosclerosis was found in 42.1%; any significant stenosis (≥50%) in 5.2%; left main, proximal left anterior descending artery, or 3-vessel disease in 1.9%; and any noncalcified plaques in 8.3% of this population. Onset of atherosclerosis was delayed on average by 10 years in women. Atherosclerosis was more prevalent in older individuals and predominantly found in the proximal left anterior descending artery. Prevalence of CCTA-detected atherosclerosis increased with increasing CAC scores. Among those with a CAC score >400, all had atherosclerosis and 45.7% had significant stenosis. In those with 0 CAC, 5.5% had atherosclerosis and 0.4% had significant stenosis. In participants with 0 CAC and intermediate 10-year risk of atherosclerotic cardiovascular disease according to the pooled cohort equation, 9.2% had CCTA-verified atherosclerosis. Prevalence estimates had excellent external validity and changed marginally when adjusted to the age-matched Swedish background population.Conclusions: Using CCTA in a large, random sample of the general population without established disease, we showed that silent coronary atherosclerosis is common in this population. High CAC scores convey a significant probability of substantial stenosis, and 0 CAC does not exclude atherosclerosis, particularly in those at higher baseline risk.
|
|
| 3. |
- Bergström, Göran, et al.
(författare)
-
Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population
- 2021
-
Ingår i: Circulation. - : Wolters Kluwer. - 0009-7322 .- 1524-4539. ; 144:12, s. 916-929
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Early detection of coronary atherosclerosis using coronary computed tomography angiography (CCTA), in addition to coronary artery calcification (CAC) scoring, may help inform prevention strategies. We used CCTA to determine the prevalence, severity, and characteristics of coronary atherosclerosis and its association with CAC scores in a general population.Methods: We recruited 30 154 randomly invited individuals age 50 to 64 years to SCAPIS (the Swedish Cardiopulmonary Bioimage Study). The study includes individuals without known coronary heart disease (ie, no previous myocardial infarctions or cardiac procedures) and with high-quality results from CCTA and CAC imaging performed using dedicated dual-source CT scanners. Noncontrast images were scored for CAC. CCTA images were visually read and scored for coronary atherosclerosis per segment (defined as no atherosclerosis, 1% to 49% stenosis, or ≥50% stenosis). External validity of prevalence estimates was evaluated using inverse probability for participation weighting and Swedish register data.Results: In total, 25 182 individuals without known coronary heart disease were included (50.6% women). Any CCTA-detected atherosclerosis was found in 42.1%; any significant stenosis (≥50%) in 5.2%; left main, proximal left anterior descending artery, or 3-vessel disease in 1.9%; and any noncalcified plaques in 8.3% of this population. Onset of atherosclerosis was delayed on average by 10 years in women. Atherosclerosis was more prevalent in older individuals and predominantly found in the proximal left anterior descending artery. Prevalence of CCTA-detected atherosclerosis increased with increasing CAC scores. Among those with a CAC score >400, all had atherosclerosis and 45.7% had significant stenosis. In those with 0 CAC, 5.5% had atherosclerosis and 0.4% had significant stenosis. In participants with 0 CAC and intermediate 10-year risk of atherosclerotic cardiovascular disease according to the pooled cohort equation, 9.2% had CCTA-verified atherosclerosis. Prevalence estimates had excellent external validity and changed marginally when adjusted to the age-matched Swedish background population.Conclusions: Using CCTA in a large, random sample of the general population without established disease, we showed that silent coronary atherosclerosis is common in this population. High CAC scores convey a significant probability of substantial stenosis, and 0 CAC does not exclude atherosclerosis, particularly in those at higher baseline risk.
|
|
| 4. |
- Bivehed, Erik, et al.
(författare)
-
Flash-comet : Significantly improved speed and sensitivity of the comet assay through the introduction of lithium-based solutions and a more gentle lysis
- 2020
-
Ingår i: Mutation research. Genetic toxicology and environmental mutagenesis. - : ELSEVIER. - 1383-5718 .- 1879-3592. ; 858
-
Tidskriftsartikel (refereegranskat)abstract
- Evaluation of primary DNA-damage is one way to identify potential genotoxic agents and for this purpose the Comet assay has, for the last decades, been used to monitor DNA single strand and double strand breaks in individual cells. Various attempts have been made to modify the different steps in the in vitro protocol for the Comet assay in order to improve its sensitivity. However, to the best of our knowledge, nobody has tried to replace the traditionally used NaOH-based electrophoresis solution (pH > 13), with another type of solution. In the present paper, using TK-6 cells exposed to different concentrations of H2O2 or ionizing radiation, we present evidence clearly showing that a low-conductive LiOH-based electrophoresis solution at pH 12.5, and a more gentle lysis procedure, significantly improved both the speed and sensitivity of the assay. The new approach, which we call the Flash-comet, is based on a lysis buffer at pH 8.5, an unwinding time of 2.5 min in a LiOH solution without EDTA at pH 12.5, and an electrophoresis time of 1 min at 150 V (5 V/cm) using the same solution.
|
|
| 5. |
- Bivehed, Erik, et al.
(författare)
-
Visualizing DNA single- and double-strand breaks in the Flash comet assay by DNA polymerase-assisted end-labelling
- 2024
-
Ingår i: Nucleic Acids Research. - : Oxford University Press. - 0305-1048 .- 1362-4962. ; 52:4
-
Tidskriftsartikel (refereegranskat)abstract
- In the comet assay, tails are formed after single-cell gel electrophoresis if the cells have been exposed to genotoxic agents. These tails include a mixture of both DNA single-strand breaks (SSBs) and double-strand breaks (DSBs). However, these two types of strand breaks cannot be distinguished using comet assay protocols with conventional DNA stains. Since DSBs are more problematic for the cells, it would be useful if the SSBs and DSBs could be differentially identified in the same comet. In order to be able to distinguish between SSBs and DSBs, we designed a protocol for polymerase-assisted DNA damage analysis (PADDA) to be used in combination with the Flash comet protocol, or on fixed cells. By using DNA polymerase I to label SSBs and terminal deoxynucleotidyl transferase to label DSBs with fluorophore-labelled nucleotides. Herein, TK6-cells or HaCat cells were exposed to either hydrogen peroxide (H2O2), ionising radiation (X-rays) or DNA cutting enzymes, and then subjected to a comet protocol followed by PADDA. PADDA offers a wider detection range, unveiling previously undetected DNA strand breaks. Graphical Abstract
|
|
| 6. |
- Brett, Calvin, et al.
(författare)
-
Humidity-Induced Nanoscale Restructuring in PEDOT:PSS and Cellulose Nanofibrils Reinforced Biobased Organic Electronics
- 2021
-
Ingår i: Advanced Electronic Materials. - : Wiley. - 2199-160X. ; 7:6, s. 2100137-
-
Tidskriftsartikel (refereegranskat)abstract
- In times where research focuses on the use of organic polymers as a base for complex organic electronic applications and improving device efficiencies, degradation is still less intensively addressed in fundamental studies. Hence, advanced neutron scattering methods are applied to investigate a model system for organic electronics composed of the widely used conductive polymer blend poly(3,4-ethylenedioxythiophene):poly(styrenesulfonate) (PEDOT:PSS) together with nanocellulose as flexible reinforcing template material. In particular, the impact of relative humidity (RH) on the nanostructure evolution is studied in detail. The implications are discussed from a device performance point of view and the changing nanostructure is correlated with macroscale physical properties such as conductivity. The first humidification (95% RH) leads to an irreversible decrease of conductivity. After the first humidification cycle, however, the conductivity can be reversibly regained when returning to low humidity values (5% RH), which is important for device manufacturing. This finding can directly contribute to an improved usability of emerging organic electronics in daily live.
|
|
| 7. |
- Frances-Soriano, Laura, et al.
(författare)
-
In Situ Rolling Circle Amplification Förster Resonance Energy Transfer (RCA-FRET) for Washing-Free Real-Time Single-Protein Imaging
- 2021
-
Ingår i: Analytical Chemistry. - : American Chemical Society (ACS). - 0003-2700 .- 1520-6882. ; 93:3, s. 1842-1850
-
Tidskriftsartikel (refereegranskat)abstract
- Fluorescence signal enhancement via isothermal nucleic acid amplification is an important approach for sensitive imaging of intra- or extracellular nucleic acid or protein biomarkers. Rolling circle amplification (RCA) is frequently applied for fluorescence in situ imaging but faces limitations concerning multiplexing, dynamic range, and the required multiple washing steps before imaging. Here, we show that Forster resonance energy transfer (FRET) between fluorescent dyes and between lanthanide (Ln) complexes and dyes that hybridize to beta-actin-specific RCA products in HaCaT cells can afford washing-free imaging of single beta-actin proteins. Proximity-dependent FRET could be monitored directly after or during (real-time monitoring) dye or Ln DNA probe incubation and could efficiently distinguish between photoluminescence from beta-actin-specific RCA and DNA probes freely diffusing in solution or nonspecifically attached to cells. Moreover, time-gated FRET imaging with the Ln-dye FRET pairs efficiently suppressed sample autofluorescence and improved the signal-to-background ratio. Our results present an important proof of concept of RCA-FRET imaging with a strong potential to advance in situ RCA toward easier sample preparation, higher-order multiplexing, autofluorescence-free detection, and increased dynamic range by real-time monitoring of in situ RCA.
|
|
| 8. |
- Jacobson, Sofie, 1961-, et al.
(författare)
-
Levels of mannose-binding lectin (MBL) associates with sepsis-related in-hospital mortality in women
- 2020
-
Ingår i: Journal of Inflammation. - : BioMed Central (BMC). - 1476-9255. ; 17
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Mannose-binding lectin (MBL) mediates the innate immune response either through direct opsonisation of microorganisms or through activation of the complement system. There are conflicting data whether MBL deficiency leads to increased susceptibility to infections or not. The aim of this study was to determine if low levels of mannose-binding lectin (MBL) predict sepsis development, sepsis severity and outcome from severe sepsis or septic shock.Method: Patients aged 18 years or more with documented sepsis within 24 h after admission to the intensive care unit were included if they had participated in a health survey and donated blood samples prior to the sepsis event. A subset of these patients had stored plasma also from the acute phase. Two matched referents free of known sepsis were selected for each case. Plasma levels MBL were determined in stored samples from health surveys (baseline) and from ICU admission (acute phase). The association between MBL and sepsis, sepsis severity and in-hospital mortality were determined with 1300 ng/mL as cut-off for low levels.Results: We identified 148 patients (61.5% women) with a first-time sepsis event 6.5 years (median with IQR 7.7) after participation in a health survey, of which 122 also had samples from the acute septic phase. Both high MBL levels in the acute phase (odds ratio [95% confidence interval]) (2.84 [1.20-6.26]), and an increase in MBL levels from baseline to the acute phase (3.76 [1.21-11.72]) were associated with increased risk for in-hospital death in women, but not in men (0.47 [0.11-2.06]). Baseline MBL levels did not predict future sepsis, sepsis severity or in-hospital mortality.Conclusions: An increase from baseline to the acute phase as well as high levels in the acute phase associated with an unfavourable outcome in women.
|
|
| 9. |
- Johansson, Camilla, 1993-
(författare)
-
Proteomic strategies for blood biomarker development in rare dystrophinopathies
- 2023
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are two rare genetic disorders of the family dystrophinopathy. They are both caused by the lack of, or reduced production of, the protein dystrophin. Due to abnormal dystrophin expression, patients experience progressive loss of muscle mass and cardio-, respiratory- and sometimes cognitive complications. DMD is the more severe form of dystrophinopathy, which manifests in young children and leads to wheelchair confinement in early teens followed by bed confinement and a shortened life expectancy. Dystrophin expression is absent or at less than 3% in DMD patients, often due to frame-shift mutations which cause protein expression to stop pre-maturely. BMD patients, on the other hand, display a higher but variable expression of dystrophin, often with large internal truncations. This partial expression results in a milder phenotype than DMD with sometimes unaffected life expectancies compared to healthy individuals. In the past decade, there has been substantial research into therapies aiming at increasing dystrophin expression in DMD patients and thereby prolonging ambulation, with the first gene-therapy gaining regulatory approval from the U.S. Food and Drug Administration (FDA) in June 2023. Current regulatory approvals for treatments of DMD patients have relied on dystrophin quantification in muscle biopsies as a biomarker and surrogate endpoint to predict a possible benefit from treatment, but these tests require repeated collection of muscle biopsies. Biomarkers are biochemical or physiological laboratory tests that measure a biological processes or condition. There is a need for monitoring biomarkers in dystrophinopathies, as well as biomarkers which can be used to predict outcome in clinical trials. As patients are often young children, it is important to develop biomarkers from less invasive and more readily available biological samples than muscle biopsies, such as blood or urine.In this thesis, we have used affinity proteomics and mass spectrometry to identify and validate biomarkers for monitoring disease progression in DMD and BMD patients from serum or plasma. The overall aim has been to identify biomarkers capable of distinguishing between patients with different levels of dystrophin expression and rates of disease progression in order to suggest gene-therapy pharmacodynamic biomarkers. In Paper I, we used suspension bead array (SBA) technology to identify biomarker candidates which reflect disease progression in DMD. Ten proteins were identified as related to disease progression. The ten biomarker candidates identified in Paper I were further analytically validated in Paper II using two orthogonal and absolute quantitative methods, parallel reaction monitoring mass spectrometry (PRM-MS) and sandwich immunoassays, which resulted in five analytically validated disease monitoring biomarkers for DMD (CA3, MYL3, LDHB, COL1A1 and FGG).Dystrophin-restoring therapies build on the hypothesis that increasing expression of internally deleted dystrophin reduces disease severity. In BMD patients, partial expression of short dystrophin molecules results in a milder phenotype than in DMD patients lacking expression of dystrophin. However, there are some differences in the nature of disease progression between DMD and BMD. In Paper III, we used Data Independent Acquisition Mass Spectrometry (DIA-MS) to study proteomic similarities and differences between DMD and BMD disease progression. This study revealed some discrepancies between disease progression biomarker candidates in the two related disorders.In Paper IV, we searched for blood biomarkers capable of reflecting changes in dystrophin expression during gene-therapy clinical trials. We identified ten proteins which correlated with dystrophin or microdystrophin expression in DMD mouse models. Out of these ten proteins, we identified that myosin light chain 3 (MYL3) declined steeper over time in dystrophinopathy patients with low or no dystrophin expression compared to patients with higher dystrophin expression. Two more biomarkers were identified in Paper IV as potentially related to dystrophin expression in muscle biopsies from both mouse models and patients. These were titin (TTN) and, interestingly, serum leakage of dystrophin. The possible presence of dystrophin in blood has not been well studied, and only one prior publication suggests that dystrophin may be a biomarker for DMD. Many DMD therapies currently in clinical trials aims at restoring dystrophin production and for those trials, the possibility of monitoring dystrophin leakage into blood could provide valuable information on therapeutic efficacy. In Paper V, we designed a proof-of-principle study to explore if dystrophin in blood can be a DMD biomarker. In conclusion, this thesis explores disease progression monitoring biomarkers and gene-therapy pharmacodynamic biomarkers for DMD and BMD. Three proteins, MYL3, TTN, and serum levels of dystrophin, are here suggested as possible gene-therapy pharmacodynamic biomarkers.
|
|
| 10. |
- Kermpatsou, Despoina, et al.
(författare)
-
Cellular responses to silencing of PDIA3 (protein disulphide-isomerase A3) : Effects on proliferation, migration, and genes in control of active vitamin D
- 2024
-
Ingår i: Journal of Steroid Biochemistry and Molecular Biology. - : Elsevier. - 0960-0760 .- 1879-1220. ; 240
-
Tidskriftsartikel (refereegranskat)abstract
- The active form of vitamin D, 1,25-dihydroxyvitamin D3, is known to act via VDR (vitamin D receptor), affecting several physiological processes. In addition, PDIA3 (protein disulphide-isomerase A3) has been associated with some of the functions of 1,25-dihydroxyvitamin D3. In the present study we used siRNA-mediated silencing of PDIA3 in osteosarcoma and prostate carcinoma cell lines to examine the role(s) of PDIA3 for 1,25-dihydroxyvitamin D3-dependent responses. PDIA3 silencing affected VDR target genes and significantly altered the 1,25-dihydroxyvitamin D3-dependent induction of CYP24A1, essential for elimination of excess 1,25-dihydroxyvitamin D3. Also, PDIA3 silencing significantly altered migration and proliferation in prostate PC3 cells, independently of 1,25-dihydroxyvitamin D3. 1,25-Dihydroxyvitamin D3 increased thermostability of PDIA3 in cellular thermal shift assay, supporting functional interaction between PDIA3 and 1,25-dihydroxyvitamin D3-dependent pathways. In summary, our data link PDIA3 to 1,25-dihydroxyvitamin D3-mediated signalling, underline and extend its role in proliferation and reveal a novel function in maintenance of 1,25-dihydroxyvitamin D3 levels.
|
|
